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BACKGROUND: Patients who speak Spanish and/or
have low socioeconomic status are at greater risk of
suboptimal glycemic control. Inadequate intensification
of anti-glycemic medications may partially explain this
disparity.
OBJECTIVE: To examine the associations between pri-
mary language, income, and medication intensification.
DESIGN: Cohort study with 18-month follow-up.
PARTICIPANTS: One thousand nine hundred and thirty-
nine patients with Type 2 diabetes who were not using
insulin enrolled in the Translating Research into Action
for Diabetes Study (TRIAD), a study of diabetes care in
managed care.
MEASUREMENTS: Using administrative pharmacy
data, we compared the odds of medication intensifi-
cation for patients with baseline A1c≥8%, by primary
language and annual income. Covariates included
age, sex, race/ethnicity, education, Charlson score,
diabetes duration, baseline A1c, type of diabetes
treatment, and health plan.
RESULTS: Overall, 42.4% of patients were taking
intensified regimens at the time of follow-up. We found
no difference in the odds of intensification for English
speakers versus Spanish speakers. However, compared
to patients with incomes <$15,000, patients with
incomes of $15,000-$39,999 (OR 1.43, 1.07-1.92),
$40,000-$74,999 (OR 1.62, 1.16-2.26) or >$75,000 (OR
2.22, 1.53-3.24) had increased odds of intensification.
This latter pattern did not differ statistically by race.
CONCLUSIONS: Low-income patients were less likely to
receive medication intensification compared to higher-
income patients, but primary language (Spanish vs.
English) was not associated with differences in intensifi-
cation in a managed care setting. Future studies are
needed to explain the reduced rate of intensification
among low income patients in managed care.
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A lthough glycemic control among patients with Type 2diabetes has improved over the last two decades, minor-
ities continue to have elevated hemoglobin A1c (A1c) values
compared to whites.1 Non-English speaking minorities are at
even greater risk of poor control, as Spanish-speaking Latinos
with Type 2 diabetes have higher A1c values than English-
speakers.2–4 Income has also been associated with glycemic
control, as low-income patients typically have higher A1c
values than higher-income patients.5 As a result of ongoing
poor metabolic control, both Spanish-speaking and low-
income patients with diabetes have disproportionately higher
rates of microvascular complications.6,7
Inadequate intensification of anti-glycemic diabetes medica-
tions, either because providers never attempt to intensify the
medication regimen (“clinical inertia”)8 or because patients are
unwilling to accept a more intensive regimen, potentially
explains suboptimal glycemic control. Low-income and/or
Spanish-speaking patients may be less likely than higher-
income and/or English-speaking patients to begin intensified
regimens for a variety of reasons, including poor patient-
provider communication, lack of patient trust in the provider
and/or the medications, concern about potential side effects,
fewer outpatient visits and therefore less frequent opportuni-
ties to intensify, or concern about the additional out-of-pocket
cost of potential new medications.9–12
While different intensification rates might explain observed
disparities in control, few published studies have examined the
association between either primary language or income and the
intensification of anti-glycemic medications. A recent paper
from the Translating Research into Action for Diabetes (TRIAD)
study found a small, non-significant difference in medication
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intensification by patient income.13 However, the analytic
sample for this study was limited to patients who completed
a two-year follow-up survey, and patients from the lowest
education and income strata were disproportionately excluded.
For the current TRIAD analysis, we hypothesized that within
a prospective cohort of managed care patients who were not
taking insulin and had suboptimal control of their diabetes at
baseline (A1c≥8.0%), Spanish-speakers would be less likely
than English-speakers to be taking intensified anti-glycemic
medication regimens at follow-up. We defined intensification as
the addition of a new medication or an increase in the dose of
an existing medication. We further hypothesized that com-
pared to higher-income patients, low-income patients within
this cohort would be less likely to be taking intensified anti-
glycemic medication regimens at follow-up.
METHODS
Setting and Participants
The TRIAD study is a multiethnic, multisite study of diabetes
care in managed care.14 TRIAD investigators collected survey
data, administrative data, and conductedmedical record review
among a prospective cohort of managed care patients with
diabetes. The TRIAD cohort was enrolled between July 2000
and August 2001 and randomly selected from 10 health plans
and 68 provider groups, which served approximately 180,000
patients. Between 5% and 10% of patients within each plan had
diabetes. The TRIAD health plans are located in different
geographic areas, and include significant numbers of Mexican
Americans (from Texas and California) as well as Puerto Ricans
and Latinos of Caribbean background (from New Jersey).
Eligibility criteria for inclusion in TRIAD included a provider
diagnosis of diabetes, age of 18 years or older, continuous
enrollment in a participating health plan for a minimum of
18 months, at least one health care claim in the previous
18 months, having received the majority of diabetes care
through the health plan, and the ability to speak either English
or Spanish. Nursing home residents, pregnant women, and
persons unable to provide informed consent were excluded.
The study protocol was reviewed and approved by Institutional
Review Boards at all participating sites. For this particular
analysis, we defined suboptimal control of diabetes as A1c≥
8.0% at baseline. However, some providers may have used a
lower A1c threshold to trigger therapy intensification. There-
fore in a sensitivity analysis, we redefined suboptimal control
as A1c≥7.0% at baseline.
We contacted 13,086 potentially eligible patients to complete
the baseline survey. Respondents completed either a comput-
er-assisted telephone or written survey. The survey was
completed by 11,927 patients (91%). As we were unsuccessful
in contacting some patients, we followed the Council of
American Survey Research Organizations (CASRO) protocol,
assuming that patients whom we could not contact or for
whom we could not confirm eligibility had the same proportion
of eligibility as those contacted.15 Under that assumption, the
CASRO response rate for the baseline survey was 69%.
For this analysis, we excluded patients with Type 1 diabetes
(n=669), defined as the subgroup less than 30 years of age who
were taking insulin but no oral anti-glycemic agents (Fig. 1).
A1c levels from the medical record were available for 7,660 of
the patients with Type 2 diabetes who completed surveys and
were continuously enrolled for the 18 months prior to baseline
and remained enrolled (allowing a gap of no more than
2 months) through the end of the administrative data window.
The majority of these patients (n=2,762) had A1c values
≥8.0% and were therefore classified as suboptimally con-
trolled. As intensification of insulin among existing users is
difficult to discern from pharmacy claims, we excluded
patients already taking insulin, resulting in a final analytic
sample of 1,939 patients (Fig. 1).
Measures
Predictor Variables. We selected primary language and income
as potential predictors of medication intensification. We
identified primary language as either English or Spanish
based on the language in which the patient elected to
complete the survey. Annual household income was
determined from a questionnaire item that classified
participants into four categories, <$15,000, $15,000–
$39,999, $40,000–$75,000, and >$75,000.
Anti-glycemic Medication Regimen Intensification. We used
pharmacy claims data to classify patients with A1c≥8% into
two mutually exclusive categories based on their baseline
medication regimens: 1) no anti-glycemic medications or 2)
Figure 1. Derivation of analytic sample.
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oral anti-glycemic medications only. We defined baseline for
each patient as the date in 2000 or 2001 on which the elevated
A1c was drawn. We classified patients as taking an oral anti-
glycemic medication at baseline if their pharmacy claims
indicated prior fills for one or more of these medications that
overlapped the date of the A1c test. As an example, a patient
who last filled a prescription for a once daily oral anti-glycemic
medication 60 days before the A1c was drawn and received a
supply of 90 days would be classified as taking an oral anti-
glycemic medication. However, another patient who last filled a
prescription for the same medication 120 days before the A1c
was tested and also received a supply of 90 days would not be
classified as taking that medication. We divided the oral anti-
glycemic medications into five subclasses: acarbose (acarbose,
miglitol), sulfonylureas (glipizide, glyburide, micronized
glyburide, chlorpropamide, glimepiride, tolazamide),
metformin, thiazolidinediones (pioglitazone, rosiglitazone),
and other (repaglinide, nateglinide). Patients could be taking
medications from multiple different subclasses at baseline.
Based on a published algorithm applied to our pharmacy
claims data, we defined two different potential measures of
medication intensification at the 18-month time point of
follow-up.13 Patients were intensified by either 1) the addition
of an anti-glycemic medication subclass by follow-up
compared to baseline (any of the five oral medication
subclasses or insulin) or 2) an increase in the dose of any
existing oral anti-glycemic medication compared to baseline.
For example, patients who were taking a medication from one
subclass at baseline and medications from two subclasses at
follow-up would be classified as having been intensified. As
switches from one medication subclass to another (e.g.
metformin to glyburide) were likely initiated due to side
effects, potential medication interactions, or reasons other
than an attempt to intensify therapy, we did not include such
changes in our definition of medication intensification.
To calculate changes in oral anti-glycemic medication
dosage over time, we created a composite variable measuring
“dose intensity units,” defined as [(quantity/days’ supply) *
dose strength] for the most recent fill before the A1c test and
the most recent fill before the calendar date exactly 18 months
later. Using data from the study cohort, we determined the
minimum and maximum values of this variable for each
specific medication, including values from baseline as well as
follow-up in the calculation. We then divided the sample into
quintiles based on the difference between the minimum and
maximum values. For example, if the minimum dose intensity
for metformin in the sample was (quantity of 60 tablets /
30 days’ supply * 500 mg strength)=1000 units, and the
maximum dose intensity was (quantity of 120 tablets /
30 days’ supply * 1000 mg strength)=4000 units, the
difference between minimum and maximum values would be
3000 units. The sample would be divided into quintiles of 3000
units / 5, or 600 units. Patients who moved from a lower
quintile at baseline to a higher quintile at follow-up were
classified as having their dose intensified. Patients who
remained in the same quintile or moved to a lower quintile
were not classified as having their dose intensified. We
considered multiple medication strengths filled on the same
day (e.g., metformin 850 mg and 500 mg) as part of the same
prescription.
Covariates. We used several survey-based covariates,
including age, gender, duration of diabetes, and education
(did not graduate high school, high school graduate, some
college). On the basis of self-identification, patients were
characterized as white, non-Latino; African American, non-
Latino; Latino; Asian/Pacific Islander; or other.16 We also
included three covariates drawn from the medical record: the
baseline A1c value, the type of diabetes treatment (oral
medications or no medications) and the Charlson comorbidity
score. The Charlson score is a commonly used measure of the
severity of comorbid conditions, which has been shown to
predict one-year mortality in cohort studies.17,18
Statistical Methods
We examined univariate distributions of all included variables,
to assess for potential miscoded values and to ensure that
variables included in continuous form approximated a normal
distribution. We then determined the distributions of different
anti-glycemic medication regimens at baseline (no medications
or oral medications) by primary language and by annual
income categories. We used a multivariate logistic regression
model to examine adjusted differences in the frequency of
intensified medication regimens at follow-up for patients with
A1c≥8% at baseline. We included all covariates in this model
simultaneously, rather than adding them in a stepwise
approach. In a second model, we added an interaction term
for race/ethnicity*annual income, to measure whether any
differences in intensification by income were influenced by
patient race/ethnicity. Because we did not have information on
drug benefit caps, which were common for managed Medicare
recipients during the time period of the study, we also
separately analyzed data limited to patients less than 65 years
of age. Finally, as the plans in the study had different
organizational structures that may have influenced intensifi-
cation rates (i.e., integrated delivery systems vs. network-
model systems), the models included a fixed effect to control
for health plan.
Analyses were conducted using the SAS statistical package
9.2 (Cary, NC). We used the Hosmer–Lemeshow test to confirm
goodness of fit. In order to ensure that the results were not
distorted by high collinearity between different measures of
socioeconomic status, we examined variance inflation factors
(VIFs). All VIFs were less than 3.0, indicating that there was no
significant multicollinearity.
RESULTS
Spanish speakers (n=64) made up 3.3% of the sample, while
the remainder was English-speakers (n=1,875, Table 1). Ap-
proximately 28% of the sample (n=551) had annual incomes <
$15,000 and $39,999, while 32% (n=610) had annual incomes
between $15,000 and $40,000, 25% (n=481) had annual
incomes between $40,000 and $75,000, and 15% (n=297)
had annual incomes over $75,000 (Table 2).
Examining the sample characteristics at baseline, there
were marked differences in education within ethnicity and
income groups (p<0.001). Spanish-speaking patients (69%)
and patients with annual incomes <$15,000 (50%) were the
least likely to have graduated high school (Tables 1 and 2).
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Spanish-speaking patients had a higher mean baseline A1c
(10.1%) than English-speaking patients (9.6%, p=0.01). How-
ever, no differences in baseline A1c by income were observed
(p=0.49).
Overall, 42.4% of patients were taking intensified regimens
at follow-up. In the multivariate analysis including all patients
with diabetes and A1c≥8% at baseline, we did not find a
statistically significant difference in the odds of taking an
intensified medication regimen for Spanish speakers com-
pared to English speakers (Table 3). However, we observed an
increase in the odds of taking an intensified medication
regimen among higher income patients. Compared to patients
with annual incomes <$15,000, patients with incomes of
$15,000-$39,999 (OR 1.43, 1.07-1.92), $40,000-$74,999 (OR
1.62, 1.16-2.26) or >$75,000 (OR 2.22, 1.53-3.24) had in-
creased odds of intensification. Higher baseline A1c values
were also associated with increased odds of intensification,
with an OR of 1.14 for each 1 percent increase in A1c. In a
second model, the interaction term for race/ethnicity*income
was not statistically significant (p=0.29), indicating that the
positive association between income and odds of intensifica-
tion was consistent within different racial groups (data not
shown).
The results of our two sensitivity analyses, namely including
all patients with A1c≥7.0% at baseline and separately limiting
the sample to patients less than 65 years of age, were similar to
the results of our main analyses.
DISCUSSION
Contrary to one of our hypotheses, we did not find differ-
ences in the odds of taking an intensified medication
regimen at follow-up for English speakers and Spanish
speakers with A1c≥8% at baseline. However, we did find
that among patients with suboptimal glycemic control,
higher patient income was associated with an increase in
the odds of intensification at follow-up. These results differ
from a prior TRIAD analysis that found a difference of 3
percentage points in intensification rates between patients
with annual incomes <$15,000 versus >$75,000.13 That
study limited the analytic sample to patients who completed
a 2-year follow-up survey. The current study had nearly
twice the sample size of the previous study and a much
larger proportion of low income participants. As shown in a
supplementary online appendix comparing results of the two
studies (Supplementary Online Appendix), the current anal-
ysis found that the likelihood of intensification was 13
percentage points higher among patients with annual
incomes of >$75,000 compared to those with annual
incomes <$15,000. The marked difference in results be-
tween two studies from the same dataset underlines the
importance of 1) clearly identifying the preferred analytic
sample to test a given hypothesis, and 2) considering how
the application of exclusion criteria will affect this sample.
There are several potential explanations for the association
between income and intensification seen in the current study.
Providers may hold unconscious stereotypes about low-
income patients, and/or be less likely to engage in patient-
centered communication with low-income patients.19–21
These or other factors may dissuade providers from discuss-
ing an intensified medication regimen with low-income
diabetic patients. Alternatively, because low-income patients
tend to express more frequent concerns, symptoms, and
psychosocial stressors compared to higher-income patients,
less time may be available to discuss chronic disease
management.19,22–24 A recent study of observed visits for
diabetic patients in poor control found that each additional
concern raised by the patient was associated with a 50%
lower likelihood of a change in antiglycemic medication.25
Cost is often an important issue when medications are newly
prescribed, and low-income patients are less able to afford
copayments for additional medication/s beyond their existing
regimen.26–28
Prior work using TRIAD data has shown that intensifica-
tion is associated with an average decrease in A1c of 0.49%
among patients with poor glycemic control.13 Furthermore,
this effect was primarily observed among patients with
Table 1. Baseline Characteristics and Unadjusted Percentages of
an Intensified Medication Regimen at Follow-Up by Primary
Language, for Participants with Hemoglobin A1c≥8%
Spanish-
speaking
patients
(n=64)
English-
speaking
patients
(n=1,875)
P value
Baseline characteristics
Age in years (SD) 60.7 (12.9) 58.7 (12.1) 0.20
Female sex (%) 53.1 51.9 0.85
Race/ethnicity <0.001
White, non-Latino (%) 0 35.0
Latino (%) 100 18.1
African American,
non-Latino (%)
0 15.5
Asian/Pacific Islander (%) 0 21.0
Other races/ethnicities (%) 0 10.5
Annual income <0.001
<$15,000 (%) 50.0 27.7
$15,000 – $39,999 (%) 42.2 31.1
$40,000 – $74,999 (%) 6.3 25.4
>$75,000 (%) 1.6 15.8
Education <0.001
<High school (%) 68.8 21.2
High school graduate (%) 15.6 31.3
Some college (%) 15.6 47.5
BMI 0.21
<25 (%) 21.9 14.0
25-29 (%) 26.6 29.3
>=30 (%) 51.6 56.6
Duration of diabetes
in years (SD)
10.5 (7.1) 10.8 (9.3) 0.80
Charlson comorbidity
score (SD)
1.75 (1.1) 2.19 (1.5) 0.02
Type of diabetes treatment
Diet controlled (%) 31.3 28.8 0.66
Oral medications only (%) 0.53
Metformin only (%) 13.6 11.6
Thiazolidinedione only (%) 0 1.7
Sulfonylurea only (%) 52.3 42.5
Acarbose only (%) 0 0.2
≥2 oral medications (%) 34.1 43.9
Baseline A1c value (SD) 10.1 (1.6) 9.6 (1.5) 0.01
Fisher’s test used for statistical comparisons of race/ethnicity and oral
medication/s used; chi-square test used for all other statistical compar-
isons
Statistically significant results shown in bold
508 Duru et al.: Language, Income, and Intensification of Anti-glycemic Medications JGIM
incomes <$15,000.15 Together with the findings in the
current study, this suggests that the specific low-income
patients who benefit the most from intensification are the
least likely to actually be intensified.
To our knowledge, this is the first study comparing
intensification of anti-glycemic medication regimens among
English-speaking and Spanish-speaking patients with sub-
optimal glycemic control. Our study included relatively few
Spanish speakers. However, examination of the observed
confidence intervals suggests that markedly lower odds of
intensification for Spanish speakers as compared to English
speakers are unlikely, and the importance of any such
differences on language-based variation in glycemic control
are probably minimal. Using the approach published by
Smith and Bates to extrapolate from our observed confidence
intervals for the primary language variable,29 we estimate
that the likelihood of the “true” OR for intensification among
Spanish speakers being less than that for English speakers is
approximately 5%. Further, the likelihood of the “true” OR for
Spanish speakers being <0.75 as compared to English speak-
ers is less than 1%. In other words, our results suggest that
differences in factors other than medication intensification
are the most likely explanations of poor glycemic control
among Spanish speakers in managed care.
One explanation for the absence of an association between
intensification and primary language, as well as the absence
of differences in earlier analyses examining other processes of
care,4 may be that managed care plans providing compre-
Table 2. Baseline Characteristics and Unadjusted Percentages of an Intensified Medication Regimen at Follow-Up by Annual Income, for
Participants with Hemoglobin A1c≥8%
Income<$15,000
(n=551)
Income $15,000-$39,999
(n=610)
Income $40,000-$74,999
(n=481)
Income>$75,000
(n=297)
P value
Baseline characteristics
Age in years (SD) 63.5 (12.1) 59.1 (12.4) 55.1 (11.1) 54.9 (9.9) <0.001
Female sex (%) 67.9 53.9 40.5 36.7 <0.001
Race/ethnicity <0.001
White, non-Latino (%) 27.0 28.1 26.7 18.3
Latino (%) 31.0 42.4 19.4 7.2
African American, non-Latino (%) 50.9 23.3 16.5 9.3
Asian/Pacific Islander (%) 16.4 33.7 29.2 20.7
Other races/ethnicities (%) 23.4 27.3 31.1 18.2
Spanish as primary language (%) 5.8 4.4 0.8 0.3 <0.001
Education <0.001
<High school (%) 50.1 19.3 7.9 3.4
High school graduate (%) 32.7 36.7 27.0 21.2
Some college (%) 17.2 43.9 65.1 75.5
BMI 0.17
<25 (%) 16.2 15.6 11.4 12.8
25-29 (%) 26.5 30.7 31.2 28.3
>=30 (%) 57.4 53.4 57.4 58.9
Duration of diabetes in years (SD) 12.7 (10.5) 11.3 (9.1) 9.1 (7.7) 9.3 (8.4) <0.001
Charlson comorbidity score (SD) 2.4 (1.8) 2.2 (1.5) 2.0 (1.2) 1.9 (1.1) <0.001
Type of diabetes treatment
Diet controlled (%) 30.1 31.0 27.9 23.4 0.11
Oral medications only 0.21
Metformin only (%) 13.4 8.8 12.1 12.8
Thiazolidinedione only (%) 0.8 1.7 2.0 2.6
Sulfonylurea only (%) 44.4 46.3 39.8 38.3
Acarbose only (%) 0.3 0.5 0 0
≥2 oral medications (%) 40.8 42.8 46.1 46.3
Baseline A1c value (SD) 9.7 (1.7) 9.6 (1.5) 9.7 (1.5) 9.6 (1.4) 0.49
Fisher’s test used for statistical comparisons of race/ethnicity and oral medication/s used; chi-square test used for all other statistical comparisons
Statistically significant results shown in bold
Table 3. Adjusted Odds of Taking an Intensified Regimen of Anti-
Glycemic Medications at Follow-Up, Among Participants with
Hemoglobin A1c≥8% at Baseline
Odds Ratio (95% CI) P value
Primary language
English 1.0
Spanish 1.60 (0.91-2.82) 0.11
Annual income
<$15,000 1.0
$15,000-$39,999 1.43 (1.07-1.92) 0.02
$40,000-$74,999 1.62 (1.16-2.26) 0.01
>$75,000 2.22 (1.53-3.24) <0.001
Race/ethnicity
White, non-Latino 1.0
Latino 0.87 (0.62-1.21) 0.39
African American, non-Latino 0.75 (0.54-1.04) 0.09
Asian/Pacific Islander 0.78 (0.57-1.08) 0.14
Other 1.05 (0.73-1.50) 0.80
Age (per 1 year) 0.997 (0.99-1.007) 0.56
Sex
Male 1.0
Female 0.95 (0.78-1.15) 0.60
Education
<High school 1.0
High school graduate 1.19 (0.90-1.58) 0.23
Some college 1.19 (0.89-1.60) 0.24
Duration of diabetes (per 1 year) 1.004 (0.993-1.02) 0.47
Baseline A1c (per 1% change) 1.14 (1.07-1.21) <0.001
Charlson comorbidity score 1.01 (0.95-1.09) 0.68
Adjusted for health plan
Statistically significant results shown in bold
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hensive care to large Latino populations invest in high-quality
interpreter services despite the lack of reimbursement from
third-party payers.30 Providers who speak Spanish are also
more likely to work in managed care settings and care for
patients with private insurance than to care for Medicaid or
uninsured patients.31
Our study has several strengths, including its longitudinal
design, large, randomly sampled cohort, and the inclusion of
participants from 10 separate health plans. However, there
are also limitations. First, we were unable to measure patient
adherence to their anti-glycemic medication regimens, which
may have resulted in some misclassification of intensification
status if patients missed refills for the entire baseline or
follow-up study window. Second, we did not analyze contin-
uous claims data between baseline and follow-up and may
have missed some patients for whom medication regimens
were successfully intensified but subsequently deintensified
before the follow-up measurement. Third, we were unable to
measure intensification with behavioral strategies or over-
the-counter herbal therapies. Finally, we could not measure
the impact of intensification on long-term outcomes such as
diabetes complications.
In summary, we found that low-income patients with
suboptimal glycemic control are less likely to be on an
intensified regimen of anti-glycemic medications at follow-up
compared to higher-income patients. However, we did not
find differences in medication intensification between Span-
ish speakers and English speakers in poor control, suggest-
ing that other factors may be responsible for persistent
language-based disparities in glycemic control. Future stud-
ies are needed to explain the reduced rate of intensification
among low-income patients in managed care settings.
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